CSIMarket Company Name, Ticker, Suppliers, else..
 
Biovie Inc   (NASDAQ: BIVI)
 

Biovie Inc's Suppliers Performance

BIVI's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
BIVI Costs vs Sales of Suppliers Growth

• More on BIVI Suppliers






Biovie Inc's Comment on Supply Chain


The company utilizes third-party suppliers and contract research organizations (CROs) to conduct clinical trials for its drug candidates bezisterim (NE3107) and BIV201. While the company oversees certain activities of these third parties, it holds ultimate responsibility for ensuring compliance with clinical protocols and regulatory standards, including current Good Clinical Practices (cGCPs) enforced by the FDA and comparable foreign authorities. During a Phase 3 trial of bezisterim (NE3107), significant protocol deviations and cGCP violations occurred at 15 study sites, resulting in the exclusion of data from those sites and notification to the FDA's Office of Scientific Investigations (OSI). The company is considering incorporating adaptive trial features or designing a new Phase 3 study. CROs assist in facilitating and monitoring the clinical trials, including the selection of sites and investigators.

Biovie Inc's Comment on Supply Chain


The company utilizes third-party suppliers and contract research organizations (CROs) to conduct clinical trials for its drug candidates bezisterim (NE3107) and BIV201. While the company oversees certain activities of these third parties, it holds ultimate responsibility for ensuring compliance with clinical protocols and regulatory standards, including current Good Clinical Practices (cGCPs) enforced by the FDA and comparable foreign authorities. During a Phase 3 trial of bezisterim (NE3107), significant protocol deviations and cGCP violations occurred at 15 study sites, resulting in the exclusion of data from those sites and notification to the FDA's Office of Scientific Investigations (OSI). The company is considering incorporating adaptive trial features or designing a new Phase 3 study. CROs assist in facilitating and monitoring the clinical trials, including the selection of sites and investigators.







BIVI's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Biovie Inc 11.63 0.00 -22.07 13
SUBTOTAL 0.00 0.00 0.00 -


Sources: Biovie Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Biovie Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.